CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.62
-0.74 (-4.03%)
At close: 4:00PM EDT

17.62 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Previous Close18.36
Open18.74
Bid17.40 x 800
Ask20.02 x 800
Day's Range17.33 - 18.97
52 Week Range10.63 - 28.81
Volume167,613
Avg. Volume138,791
Market Cap578.74M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

    Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. “So far, 2020 has proven to be a transformational time for Crinetics, highlighted by the positive interim Phase 2 results for paltusotine, our lead product candidate for the treatment of acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.

  • GlobeNewswire

    Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten public offering of 8,222,500 shares of its common stock, including 1,072,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $14.00 per share. Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine and its other research and development programs, and for working capital and general corporate purposes. The securities described above were offered by Crinetics pursuant to a shelf registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC).

  • GlobeNewswire

    Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares to be sold in the offering are being sold by Crinetics. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,072,500 shares of common stock.

  • GlobeNewswire

    Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics.

  • GlobeNewswire

    Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update

    Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands, octreotide or lanreotide. Results as of a February 23, 2020 data cutoff showed that acromegaly patients switching from injectable depot therapy to once daily oral paltusotine (formerly CRN00808) maintained IGF-1 levels previously achieved with commercially available depot injections of somatostatin receptor ligands (SRLs).

  • GlobeNewswire

    Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, March 09, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

    SAN DIEGO, Feb. 19, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    SAN DIEGO, Jan. 08, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 12, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 25, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 03, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Aug. 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

  • GlobeNewswire

    Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism

    Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it would receive up to approximately $0.9 million in continued funding under its Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) of the National Institutes of Health (NIH). The funds are being used to support the ongoing research and development of Crinetics’ nonpeptide somatostatin agonists for congenital hyperinsulinemias (CHI).

  • GlobeNewswire

    Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors

    Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Stephanie S. Okey, M.S. to its board of directors as an independent board member. “Stephanie’s extensive experience with the regulatory approval process, launch and commercialization of rare and orphan disease products makes her a valuable addition to our board,” said Scott Struthers, Ph.D., President and Chief Executive Officer of Crinetics.